Most importantly, similar to ALK gene fusions (∼5% of the cases) in non‐small cell lung cancer patients, who benefit from ALK kinase inhibitors; the higher incidence of RAF rearrangements positive PCa patients (∼5% in Indian PCa) reported in this study may respond to the FDA‐approved RAF inhibitors or MEK inhibitors. This evidence concerns the gene MAP2K7 and lung cancer.